AMARIN CORP PLC\UK Form 8-K December 19, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 19, 2012

Amarin Corporation plc

(Exact name of registrant as specified in its charter)

England and Wales (State or other jurisdiction

0-21392 (Commission

Not applicable (I.R.S. Employer

of incorporation) File Number) Identification No.)

Edgar Filing: AMARIN CORP PLC\UK - Form 8-K

2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2,


Ireland (Address of principal executive offices)

Not applicable (Zip Code)

Registrant s telephone number, including area code: +353 1 6699 020

Not Applicable

Former name or former address, if changed since last report



- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: AMARIN CORP PLC\UK - Form 8-K

Item 8.01. Other Events

On December 19, 2012, Amarin Corporation plc (the $\underline{\text{Company}}$) and a subsidiary completed the previously announced financing transaction with Biopharma Secured Debt Fund II Holdings Cayman LP, a Cayman Islands exempted limited partnership.

Edgar Filing: AMARIN CORP PLC\UK - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 19, 2012 Amarin Corporation plc

By: /s/ John Thero John Thero President